Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Surrounded by family and friends, Lane rang the bell, which symbolizes the end of cancer treatments, at Brenner Children’s ...

Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) ...

Topline results from a trial evaluating AbbVie and Genmab's epcoritamab to treat a type of lymphoma demonstrated an improvement in progression-free survival, the companies said. AbbVie and Genmab said ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Danish drugmaker Genmab said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study.